-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
-
Alex Bodi appointed Vice President of SCANDIC FINANCE GROUP
-
Alex Bodi, numit vicepreședinte al grupului SCANDIC FINANCE
-
Elon Musk jokes about moving businesses to space after US midterms
-
West Mercia Police opens 2027 cadet applications to Worcestershire teenagers
-
NHS to test blood screening designed to detect 13 cancers earlier
-
Worcestershire road closures announced for Remembrance Sunday events
-
Democrats near House takeover as voters judge Trump presidency
-
UBC professor describes police call after Galloway remark as act of care
-
Lethbridge submits interest in provincial ground ambulance contract
-
False voting claims spread rapidly during US Election Day
-
The Cat in the Hat expands its stakes to cosmic scale in animated reboot
-
Lettermen co-founder Tony Butala dies at 87
-
Byron Donalds wins Florida governor race and underscores Republican strength
-
James Talarico defeats Ken Paxton in historic Texas Senate result
-
Commentator predicts possible US strike on Iran as regional tensions rise
-
Goa plans relationship-readiness course amid concern over divorces
-
Manchester United climbs standings after 3-2 Champions League win over Roma
-
India introduces four-layer motor insurance choice from December 15
-
Mutual fund returns show shifting leaders across market-cap categories
-
Polaris Renewable Energy Announces Q3 2026 Results
-
Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
-
Polaris Renewable Energy Declares Quarterly Dividend
-
Nikkei Falls 1.42% as AI Sector Faces Pressure Post-US Elections
-
BHEL wins Adani Power projects valued at up to ₹28,000 crore
-
IndiGo holds talks with Embraer over potential order for 100 aircraft
-
India seeks threefold increase in coal stocks to prevent summer power shortages
-
Real Madrid Visits AEK Athens in Champions League Liga Phase
-
Indian companies report mixed second-quarter results on November 4
-
Indus Towers expands solar-powered network to 50,000 telecom sites
-
KKR secures Indian regulator approval for Gentari Renewables investment
-
Equitas Small Finance Bank rebounds after naming interim chief executive
-
Bharti Airtel revenue expected to grow at double-digit pace in second quarter
-
Titan quarterly profit seen rising as jewellery business drives growth
-
Indian crude-sensitive shares gain after 13% oil-price decline
-
Kuwait finance minister holds economic cooperation talks at COMCEC
-
Stocks and dollar fall as Democratic election gains reshape markets
-
Abdul El-Sayed declares victory in Michigan Senate contest
-
Kuwait marks key events and anniversaries from national history
-
Democrats capture US Congress in sweeping midterm victory
-
Trump congratulates Democrats and signals willingness to cooperate
-
Manchester United rallies past Roma as PSG dominates in Champions League
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities
Acquisition adds proven PzF™ thin-film surface modification technology, specialized blood- and tissue-contacting device expertise and a West Coast testing facility
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices.
The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio.
"As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address increasingly complex blood-contacting applications," said Charlie Olson, President, Surmodics Coatings, Biomaterials and Catheter Technologies. "PzF gives our customers another proven thin-film surface modification to consider as they develop the next generation of devices."
PzF is an ultra-thin polymer surface modification technology designed to enhance hemocompatibility for blood and tissue-contacting medical devices and materials. With more than 20 years of history in medical device applications, PzF has received six FDA clearances and one PMA approval and is commercialized today in cardiovascular and embolization technologies. The technology can be applied to a variety of substrates ranging from metals, polymers, medical fabrics and even tissue. Device applications include stents, grafts, catheters, filters, nitinol devices, ePTFE devices and PET/polyester materials.
The acquisition also expands Surmodics' analytical testing capabilities. Alta Biomed's Carlsbad facility brings established expertise in hemocompatibility and particulate testing, including coating integrity assessment, acute particulate testing and dynamic human blood loop testing used to compare coated and uncoated devices.
With the acquisition complete, Surmodics has assumed Alta Biomed's ongoing operations in Carlsbad. The location expands Surmodics' geographic footprint and provides a West Coast presence closer to many medical device companies in California and the surrounding region. Existing Alta Biomed programs will continue as the company's PzF surface modification and testing capabilities are integrated into the broader Surmodics organization.
"This acquisition is a natural and exciting next step for our team. Joining Surmodics provides the scale, established leadership and global access to reach more patients with our advanced coating technologies," said Chris Nocera, VP of Engineering, Alta Biomed, who will lead the Carlsbad site.
The acquisition further advances Surmodics' strategy to build a differentiated portfolio of coating and surface modification technologies, specialty biomaterials and technical services that can support medical device companies from early feasibility and technology selection through testing, process development and commercialization.
About Alta Biomed
Alta Biomed, formerly Alta Biomaterials and a portfolio company of Nidus Biomedical, is a medical device coating services and testing company based in Carlsbad, California. The company specializes in PzF thin-film surface technology for vascular and other medical devices and works with medical device developers on coating feasibility, process development, coating integrity assessment, particulate testing and dynamic human blood loop testing. For more information visit www.altabiomed.com/.
About Surmodics
Surmodics provides performance coatings, surface technologies, specialty polymers, analytical testing, drug delivery and catheter development capabilities to the medical device industry. With nearly 50 years of experience in surface technology and biomaterials, Surmodics works with medical device developers to improve device performance and support programs from early-stage feasibility through commercialization. For more information, visit www.surmodics.com.
Media Contact
Jay Thompson
[email protected]
SOURCE: Surmodics Inc.
View the original press release on ACCESS Newswire
B.Godinho--PC